Drug profile · INN
trastuzumab-anns
KANJINTI
- US status
- approved
- Patents linked
- 0
- News articles
- 0
Quick answer
trastuzumab-anns (KANJINTI) is an FDA-listed pharmaceutical active ingredient. Route of administration: single-dose. Current US regulatory status: approved.
Key facts
INN trastuzumab-anns
Brand KANJINTI
Route SINGLE-DOSE
Formulation VIAL
Frequently asked questions
What is trastuzumab-anns?
trastuzumab-anns (KANJINTI) is an FDA-listed pharmaceutical active ingredient. Route of administration: single-dose. Current US regulatory status: approved.
What is the brand name for trastuzumab-anns?
KANJINTI is a marketed brand name for trastuzumab-anns. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of trastuzumab-anns?
trastuzumab-anns has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.